68 results
8-K
EX-99.1
IMCR
Immunocore Holdings plc
31 May 24
Regulation FD Disclosure
4:21pm
specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma. This is the first molecule developed using Immunocore’s ImmTAC
8-K
EX-99.1
IMCR
Immunocore Holdings plc
30 May 24
Other Events
5:22pm
. KIMMTRAK specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma. This is the first molecule developed using Immunocore’s
8-K
EX-99.1
IMCR
Immunocore Holdings plc
8 May 24
Immunocore reports first quarter financial results and provides a business update
7:13am
function. KIMMTRAK specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma. This is the first molecule developed using
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
paid us an initial upfront payment of $20 million in exchange for exclusive licenses to two of our targets, MAGE-A4 and an undisclosed target … of KIMMTRAK to patients in France is also required in the assessment of rebates payable. We apply judgement to assess internal targets, pricing information
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
to expanding access to our product, governmental affairs, sales, cash and operating expense targets, investor relations and business development
Be the Best … on performance against strategic, corporate targets and the overall performance of the business over the year, 110% of the target bonus was awarded, which
PRE 14A
slqa4 zmu
2 Apr 24
Preliminary proxy
4:45pm
8-K
EX-99.1
ro64qu8obuac
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
10-K
9awklgi5 0a1n86neh44
28 Feb 24
Annual report
7:33am
8-K
EX-99.2
4it3e4l7
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
8-K
EX-99.1
8or3s
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
6-K
EX-99.3
vht zeu016vuo
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.2
u3u748zb f20wmf
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
anoe1f87u88k5
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
19pcvp94zhlbz
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
tw6k1av
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
6-K
EX-99.3
3auae5cn14wv35x9pfu
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.2
auh6k74e9pgnt9 l4yfs
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.1
zel6bycyfvjvm 99
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
6-K
EX-99.1
fmr60x5r4p4nce9
18 Apr 23
Current report (foreign)
4:13pm
6-K
EX-99.1
5pc24j4jy9uhu6
2 Dec 22
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
5:08pm